When Does Hormone Therapy Fail for Prostate Cancer?
Title: When Does Hormone Therapy Fail for Prostate Cancer?Category: Health and LivingCreated: 6/9/2021 12:00:00 AMLast Editorial Review: 6/9/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 9, 2021 Category: Cancer & Oncology Source Type: news
Using IGF-I to Monitor Long-Acting Growth Hormone Therapy Using IGF-I to Monitor Long-Acting Growth Hormone Therapy
What is the optimal timing of IGF-I measurement for the monitoring of long-acting growth-hormone therapy? This commentary explores the issues.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 7, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Hormone Therapy, Mammographic Density and Breast Cancer Risk Hormone Therapy, Mammographic Density and Breast Cancer Risk
What have we learned about the joint effect of menopausal hormone therapy and mammographic density on the risk for breast cancer?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 2, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Challenging Gender-Affirming Hormone Therapy Prescribing Challenging Gender-Affirming Hormone Therapy Prescribing
This commentary explores the findings from a new study that challenge standard prescribing recommendations for gender-affirming hormone therapy.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 31, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Long-Term ERLEADA ® (apalutamide) Patient-Reported Outcomes Data in Metastatic Castration-Sensitive Prostate Cancer Demonstrate Maintenance of Health-Related Quality of Life for Patients
May 26, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced patient-reported outcomes (PRO) data from the pre-specified final analysis of the Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC). The TITAN study previously demonstrated statistically significant improvement in overall survival (OS) after a median follow-up of 44 months in patients receiving ERLEADA® plus androgen deprivation therapy (ADT).1 The new PRO data showed that the addition of ERLEADA® to ADT maintained patients’ health-related quality of life (HRQoL) and ...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Researchers aim to modify fragmented health care system to reduce HIV incidence among trans women
(University of Texas Health Science Center at Houston) There are an estimated one-million transgender adults living in the US and an estimated 14% of transgender women are living with HIV. Researchers at UTHealth are studying if a combination intervention that combines HIV prevention services and hormonal therapy, supported by peer health navigation, will reduce HIV acquisition among this patient population. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 21, 2021 Category: Infectious Diseases Source Type: news
CDK inhibitors may improve immune therapy effectiveness for recurrent breast cancer
(Ohio State University Wexner Medical Center) A class of drugs that inhibits breast cancer progression when used with hormonal therapy might also boost the effectiveness of immune therapy in cases of recurrent, metastatic breast cancer, according to a new study led by researchers atThe Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 10, 2021 Category: International Medicine & Public Health Source Type: news
Success in LGBTQ+ Medicine Requires Awareness of Risk Success in LGBTQ+ Medicine Requires Awareness of Risk
Cross-sex hormone therapy is not without risks, said Dr Megan McNamara, including ' very high ' risks of erythrocytosis among transgender men and venous thromboembolic disease among transgender women.Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 4, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news
Mayo Clinic Minute: Lifestyle changes to manage menopause symptoms
The average healthy woman begins menopause at 51, though some women will begin in their 40s or in their late 50s. It's a natural biological process that marks the time a woman ends her menstrual cycle. Mood swings, hot flashes and difficulty sleeping are common symptoms that can be effectively managed with hormone therapy. Lifestyle [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 3, 2021 Category: Databases & Libraries Source Type: news
Growth Hormone Therapy in Adults With Prader-Willi Syndrome Growth Hormone Therapy in Adults With Prader-Willi Syndrome
Should growth hormone therapy have a role in the management of adults with Prader-Willi syndrome?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 29, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Associations of Endometriosis and HT With Hyperlipidemia Associations of Endometriosis and HT With Hyperlipidemia
Are endometriosis and related use of hormone therapy associated with an increased risk of developing hyperlipidemia?American Journal of Epidemiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2021 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news
AHA Offers Guidance for CVD Risk in Breast, Prostate Cancer
Patients with breast, prostate cancer who are receiving hormonal therapy more likely to develop cardiovascular risk factors (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 26, 2021 Category: Cancer & Oncology Tags: Cardiology, Gynecology, Oncology, Pharmacy, Urology, Journal, Source Type: news
Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormones
(American Heart Association) Patients with breast and prostate cancers who are treated with hormonal therapies have an increased risk of heart attack and/or stroke as they age.The increased likelihood of a heart attack or stroke is greater in patients who already have two or more cardiovascular risk factors such as high blood pressure, high cholesterol, obesity, smoking or a family history of heart disease or stroke.The longer the duration of hormonal therapy, the higher the risk of cardiovascular disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 26, 2021 Category: International Medicine & Public Health Source Type: news
Transgender Hormone Therapy Linked to Blood Pressure Changes Transgender Hormone Therapy Linked to Blood Pressure Changes
Blood pressure elevations in transgender males and a subset of transgender females are seen before and soon after gender-affirming hormone therapy initiation.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 19, 2021 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
Gender-Affirming Hormone Therapy Tied to Systolic BP Changes
MONDAY, April 19, 2021 -- Within two to four months of starting gender-affirming hormone therapy (GAHT), transfeminine adults have lower mean systolic blood pressure and transmasculine adults have higher mean systolic blood pressure, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 19, 2021 Category: Pharmaceuticals Source Type: news
